| Size | Price | Stock |
|---|---|---|
| 5mg | $81 | In-stock |
| 10mg | $150 | In-stock |
| 25mg | $300 | In-stock |
| 50mg | $560 | In-stock |
| 100mg | $900 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-N0836 |
| M.Wt: | 425.60 |
| Formula: | C27H39NO3 |
| Purity: | >98 % |
| Solubility: | DMSO : 1 mg/mL (ultrasonic) |
Jervine (11-Ketocyclopamine) is an orally active steroidal alkaloid and Hedgehog signaling pathway inhibitor. Jervine can be isolated from Veratrum californicum. Jervine regulates Wnt, inhibits the AKT/mTOR signaling pathway, and activates the AMPK signaling pathway. Jervine induces DNA damage, Apoptosis, Autophagy, ROS production and Mitochondrial damage. Jervine exhibits anti-cancer and anti-inflammatory activities. Jervine reduces tumor growth rate and weight in xenograft models. Jervine can be used in studies related to triple-negative breast cancer, nasopharyngeal carcinoma and non-small cell lung cancer[1][2][3].
In Vitro:Jervine (10-40 μM; 48 h) dose-dependently represses Hedgehog signaling in 5-8F and C666-1 NPC cells, and suppression of GLI1 is necessary for Jervine-induced autophagy, as shown by increased LC3B-II conversion and puncta formation with GLI1 knockdown[2].
Jervine (1.25-20 μM; 1-4 days) time- and dose-dependently inhibits the proliferation of A549 and H1299 NSCLC cells, with 20 μM jervine causing the strongest reduction after 4 days of incubation[3].
Jervine (5-10 μM; 48 h) significantly induces apoptosis in A549 and H1299 NSCLC cells, with 10 μM causing a stronger apoptotic response[3].
Jervine (5-10 μM; 48 h) significantly induces apoptosis in A549 and H1299 NSCLC cells, as detected by Hoechst 33258 staining[3].
Jervine (5-10 μM; 48 h) dose-dependently upregulates markers of apoptosis (cleaved Caspase-3, cleaved PARP) and autophagy (LC3II) in A549 and H1299 NSCLC cells[3].
Jervine (5-10 μM; 48 h) dose-dependently represses AKT/mTOR signaling in A549 and H1299 NSCLC cells, as evidenced by reduced p-AKT and p-mTOR expression[3].
In Vivo:Jervine (20 mg/kg; p.o.; daily; 24 days) significantly suppresses nasopharyngeal carcinoma xenograft tumor growth in BALB/c nude mice by inducing apoptosis and autophagy through inhibition of Hedgehog signaling, with no detectable toxicity[2].
Jervine (20 mg/kg; p.o.; daily; 24 days)'s suppression of nasopharyngeal carcinoma xenograft tumor growth in BALB/c nude mice is largely dependent on induction of autophagy, as co-treatment with the autophagy inhibitor 3-MA (HY-19312) abrogates its anti-tumor effects[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.